Format

Send to

Choose Destination
J Am Acad Dermatol. 2015 Nov;73(5 Suppl 1):S66-9. doi: 10.1016/j.jaad.2015.07.040.

Remission of refractory pyoderma gangrenosum, severe acne, and hidradenitis suppurativa (PASH) syndrome using targeted antibiotic therapy in 4 patients.

Author information

1
INSERM U1151 eq. 11, Université Paris Descartes - Sorbonne Paris Cité, Laboratory of Microbiology, Necker-Enfants Malades Hospital, Paris, France.
2
INSERM UMR 1163, Laboratory of Genetic Skin Diseases: from Disease Mechanism to Therapies, Paris Descartes - Sorbonne Paris Cité University, Imagine Institute, Paris, France.
3
Institut Pasteur, Medical Center, Paris, France.
4
Department of Infectious Diseases, Hôpital Necker-Enfants Malades, Paris, France.
5
Institut de Proctologie Léopold Bellan, Hôpital St Joseph, Paris, France.
6
Department of Gastroenterology, Centre Hospitalier, Salons de Provence, France.
7
Institut Pasteur, Medical Center, Paris, France. Electronic address: anassif@pasteur.fr.

Abstract

Pyoderma gangrenosum, severe acne, and suppurative hidradenitis (PASH) syndrome can prove refractory to treatment and is characterized by relapses and recurrences. The combination of antibiotic therapy and surgery can produce success in the management of the syndrome. Acute treatment is required, but maintenance therapy is also necessary to prevent disease relapse. The response to antibiotic therapy is hypothesis generating, raising the issue of a modified host response. To date, anecdotal reports support the use of surgery and medical therapy, but controlled investigations with extended follow-up are necessary to substantiate preliminary data observed with individual cases.

KEYWORDS:

PASH syndrome; acne fulminans; antibiotic therapy; hidradenitis suppurativa; microbiome host disease; pyoderma gangrenosum; remission; severe acne

PMID:
26470620
DOI:
10.1016/j.jaad.2015.07.040
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center